Simplified Method of Staining Endospores

Dr. Kronengold was named Aperion’s Chief Scientific Officer in February 2010. He has over 15 years of regenerative biomaterials industry experience. Prior to joining Aperion, he was Vice President of Biomaterials Research and an executive officer of Kensey Nash Corporation. At Kensey Nash, Dr.

Kronengold managed an R&D team of over 30 employees and commercialized numerous biomaterials-based regenerative medicine products in the fields of orthopaedics, general surgery and cardiology.

topical wound dressings and a urinary incontinence device.

Under Dr. Kronengold’s supervision, the R&D groups of Kensey Nash developed products for articular cartilage regeneration, synthetic bone grafting and soft tissue repair utilizing extracellular matrices. Dr. Kronengold’s business unit accounted for approximately 40% of Kensey Nash’s total revenues.

As well as the ability to encourage a biological response to an implant. Currently, Aperion is the only company that is pursuing an animal-derived anterior cruciate ligament (ACL) implant.

His team published or presented over 45 papers and was awarded numerous patents. Prior to Kensey Nash, Dr. Kronengold was a consultant to Integra LifeSciences where he was a project manager for a second-generation artificial skin product and led development efforts.

He holds a Ph.D. and M.S. in Biomedical Engineering from UMDNJ-Robert Wood Johnson Medical School / Rutgers University and a B.S. in Chemical Engineering from Carnegie Mellon University

Leave a Reply

Your email address will not be published. Required fields are marked *